Copeland Capital Management LLC continued to hold its position in Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,997 shares of the company’s stock at the close of the 2nd quarter. Copeland Capital Management LLC’s holdings in Johnson & Johnson were worth $396,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Lenox Wealth Advisors Inc. boosted its stake in shares of Johnson & Johnson by 0.7% in the 1st quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after purchasing an additional 6 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Johnson & Johnson by 241.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares during the last quarter. Ullmann Financial Group Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at $186,000. Taylor Wealth Management Partners boosted its stake in shares of Johnson & Johnson by 19.8% in the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after purchasing an additional 250 shares during the last quarter. Finally, Foundation Resource Management Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at $204,000. 65.90% of the stock is currently owned by institutional investors.

WARNING: “Copeland Capital Management LLC Has $396,000 Holdings in Johnson & Johnson (JNJ)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/24/copeland-capital-management-llc-has-396000-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson (NYSE JNJ) traded down 0.27% on Friday, reaching $131.39. 4,334,862 shares of the company’s stock traded hands. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The firm’s 50 day moving average price is $132.79 and its 200 day moving average price is $129.43. The company has a market cap of $352.65 billion, a PE ratio of 22.23 and a beta of 0.79.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.74 EPS. On average, equities analysts expect that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is 56.76%.

A number of research firms have recently commented on JNJ. J P Morgan Chase & Co upped their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research note on Wednesday, August 16th. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. BidaskClub raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. UBS AG reaffirmed a “buy” rating and issued a $148.00 price objective (up from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Finally, BTIG Research lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 target price on the stock. in a research note on Friday, July 21st. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $135.29.

In related news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.